Predictors of Pneumococcal Conjugate Vaccine Immunogenicity among Infants and Toddlers in an American Indian PnCRM7 Efficacy Trial

O'Brien, Katherine L.; Moïsi, Jennifer; Moulton, Lawrence H.; Madore, Dace; Eick, Angelia; Reid, Ray; Weatherholtz, Robert; Millar, Eugene; Hu, Diana; Hackell, Jill; Kohberger, Robert; Siber, George; Santosham, Mathuram
July 2007
Journal of Infectious Diseases;7/1/2007, Vol. 196 Issue 1, p104
Academic Journal
Background. Pneumococcal conjugate vaccines are important for the prevention of serious illness and death among infants. Factors associated with pneumococcal conjugate vaccine immunogenicity have not been explored. Methods. Children <24 months of age received 2, 3, or 4 doses of 7-valent pneumococcal conjugate vaccine (PnCRM7) or control vaccine depending on age at enrollment. Serum samples were tested for serotype-specific antibodies by enzyme-linked immunosorbant assay. Multiple linear regression was used to determine predictors of immunogenicity.Results. Among 315 PnCRM7-vaccinated subjects and 295 control subjects enrolled at <7 months of age, geometric mean concentrations (GMCs) of antibodies were significantly higher after dose 3 than after dose 2 for all serotypes except type 4. The proportion of subjects with antibody concentrations ⩾5.0 mg/mL was higher for all serotypes, but the proportion with concentrations ⩾0.35 mg/mL was higher only for types 6B and 23F. Threedose and 2-dose regimens for those 7–11 and 12–23 months of age, respectively, were highly immunogenic. Increased maternal antibody concentrations were associated with reduced responses to dose 1 and 3 but not to dose 4 of PnCRM7. Conclusions. Maternal antibody is associated with a reduced infant response to PnCRM7 but does not interfere with immune memory. In infants, a third priming dose increases the antibody GMC and the proportion achieving an antibody concentration ⩾5.0 mg/mL but has little impact on the proportion achieving a concentration ⩾0.35 mg/mL.


Related Articles

  • Differential B-Cell Memory Around the 11-Month Booster in Children Vaccinated With a 10- or 13-Valent Pneumococcal Conjugate Vaccine. van Westen, Els; Wijmenga-Monsuur, Alienke J.; van Dijken, Harry H.; van Gaans-van den Brink, Jacqueline A. M.; Kuipers, Betsy; Knol, Mirjam J.; Berbers, Guy A. M.; Sanders, Elisabeth A. M.; Rots, Nynke Y.; van Els, Cécile A. C. M. // Clinical Infectious Diseases;8/1/2015, Vol. 61 Issue 3, p342 

    Background. Both the 10- and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13) induce immunological memory against Streptococcus pneumoniae infections caused by vaccine serotypes. In addition to comparing serum antibody levels, we investigated frequencies of serotype-specific plasma...

  • Anticapsular Serum Antibody Concentration and Protection against Pneumococcal Colonization among Children Vaccinated with 7-Valent Pneumococcal Conjugate Vaccine. Millar, Eugene V.; O'Brien, Katherine L.; Bronsdon, Melinda A.; Madore, Dace; Hackell, Jill G.; Reid, Raymond; Santosham, Mathuram // Clinical Infectious Diseases;5/1/2007, Vol. 44 Issue 9, p1173 

    Background. Pneumococcal conjugate vaccines prevent invasive and noninvasive disease due to infection with vaccine serotypes. Pneumococcal conjugate vaccines also prevent nasopharyngeal acquisition of vaccine serotypes, although the mechanism is incompletely understood. Methods. An efficacy...

  • Avidity and Subclasses of IgG after Immunization of Infants with an 11-Valent Pneumococcal Conjugate Vaccine with or without Aluminum Adjuvant. Wuorimaa, Tomi; Dagan, Ron; Vakevainen, Merja; Bailleux, Fabrice; Haikala, Raili; Yaich, Mansour; Eskola, Juhani; Kayhty, Helena // Journal of Infectious Diseases;11/1/2001, Vol. 184 Issue 9, p1211 

    Finnish and Israeli infants received an 11-valent mixed-carrier pneumococcal conjugate vaccine with or without aluminum adjuvant at 2, 4, 6, and 12 months of age. The relative avidity of serotype 1-, 5-, 6B-, 14-, 19F-, and 23F-specific IgG antibodies in serum obtained at 7, 12, and 13 months of...

  • Immune globulin/pneumococcal vaccine.  // Reactions Weekly;12/11/2010, Issue 1331, p20 

    The article describes the case of a 2-year-old boy who developed serum sickness following administration of immune globulin and pneumococcal vaccine.

  • Similar antibody levels found with four PCV13 immunization schedules.  // Infectious Diseases in Children;Oct2013, Vol. 26 Issue 10, p19 

    The article discusses the similar antibody levels found in four different 13-valent pneumococcal conjugate vaccine (PCV13) immunization schedules in infants after booster dose at 12 months according to Doctor of Medicine Judith Spijkerman of Wilhelmina Children's Hospital in the Netherlands.

  • Efforts to raise supply of two prophylactic agents. Marwick, Charles // JAMA: Journal of the American Medical Association;2/15/95, Vol. 273 Issue 7, p530 

    Reports on the shortage of prophylactic agents, pneumococcal vaccine and intramuscularly administered immunoglobulin as a result of the increase in popularity of immunizations. Sales of vaccines; Administration of vaccines by physicians.

  • Taking a Shot at Ear Infections. Neifert, Marianne // Baby Talk;May2000, Vol. 65 Issue 4, p22 

    Reports that pneumococcal conjugate vaccine (PCV) promises to be a welcome addition to the routine childhood immunizations that protect little ones from serious illness. Information on a version of the PCV called the Prevnar vaccine; Infant age when the vaccine must be given by injection.

  • Newborn vaccination with pneumococcal conjugate vaccine promising. Blazek, Nicole; Volansky, Rob; Zacharyczuk, Colleen // Infectious Diseases in Children;Oct2009, Vol. 22 Issue 10, p17 

    The article focuses on a study which examined the safety and immunogenicity of seven-valent pneumococcal conjugate vaccine (PCV7) in newborn infants.

  • Similar antibody levels found among four PCV13 immunization schedules.  // Infectious Disease News;Oct2013, Vol. 26 Issue 10, p48 

    The article discusses a study published in a 2013 issue of "JAMA: The Journal of the American Medical Association" that found similar antibody levels among 13-valent pneumococcal conjugate vaccine (PCV7) immunization schedules for infants.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics